- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00948558
Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT
August 4, 2009 updated by: Huashan Hospital
Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).
- To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors.
- To validate a pharmacokinetic model which has been established in a formal paper.
- To create a safe and effective RCA-CRRT protocol.
Study Overview
Status
Unknown
Study Type
Observational
Enrollment (Anticipated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Feng Ding, Professor
- Phone Number: 86-02152888135
- Email: ding_feng@hotmail.com
Study Locations
-
-
-
Shanghai, China, 200040
- Recruiting
- Huashan Hospital
-
Contact:
- Feng Ding, doctor
- Phone Number: 81-02152888135
- Email: ding_feng@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
the subjects will be selected from a university teaching hospital in Shanghai, China.
Description
Inclusion Criteria:
- healthy individuals, none-pregnant
- diagnosed with acute renal failure according to RIFLE criteria
- ARF with hepatic insufficiency
- ARF with MODS or sepsis
- within informed consent
Exclusion Criteria:
- used drugs with citrate within one week
- infused with blood,plasma or platelet or undergone plasma exchange therapy within 48 hours
- serious alkalosis with PH>7.55
- serious lactic acidosis
- not in resuscitation state
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Anticipated)
December 1, 2010
Study Completion (Anticipated)
September 1, 2011
Study Registration Dates
First Submitted
July 28, 2009
First Submitted That Met QC Criteria
July 28, 2009
First Posted (Estimate)
July 29, 2009
Study Record Updates
Last Update Posted (Estimate)
August 6, 2009
Last Update Submitted That Met QC Criteria
August 4, 2009
Last Verified
August 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2009-108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Insufficiency
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
BeiGeneCompletedHepatic Insufficiency & Healthy SubjectsUnited States
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Cardiox CorporationTerminatedHepatic Failure
-
Novartis PharmaceuticalsCompletedHepatic FailureUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
Biotie Therapies Inc.Acorda TherapeuticsTerminatedHepatic ImpairmentUnited States
-
PfizerMedivation, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisUnknownFulminating Hepatic FailureFrance
-
National Taiwan University HospitalUnknownLiver Failure | Critical CareTaiwan